CN104434921A - Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof - Google Patents
Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof Download PDFInfo
- Publication number
- CN104434921A CN104434921A CN201410617528.3A CN201410617528A CN104434921A CN 104434921 A CN104434921 A CN 104434921A CN 201410617528 A CN201410617528 A CN 201410617528A CN 104434921 A CN104434921 A CN 104434921A
- Authority
- CN
- China
- Prior art keywords
- oral formulations
- intestinal tract
- tract disease
- bacterial intestinal
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 244000144972 livestock Species 0.000 title abstract description 5
- 208000028774 intestinal disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 24
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960001180 norfloxacin Drugs 0.000 claims abstract description 21
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims abstract description 20
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 10
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 10
- 229960004853 betadex Drugs 0.000 claims abstract description 10
- 238000000576 coating method Methods 0.000 claims abstract description 10
- 239000011248 coating agent Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims description 28
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000008016 pharmaceutical coating Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- -1 suspensoid Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 235000019629 palatability Nutrition 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 11
- 244000144977 poultry Species 0.000 description 6
- 235000013594 poultry meat Nutrition 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The aim of the invention is to provide an oral preparation for treating bacterial intestinal diseases of livestock, a preparation method and an application thereof. The oral preparation is characterized by consisting of a medicinal composition, a coating material and medicinal accessories, wherein the medicinal composition consists of norfloxacin and berberine hydrochloride, the coating material is beta-cyclodextrin, and the mass ratio of the medicinal composition to the coating material is 2:1. The norfloxacin and the berberine hydrochloride are adopted in the oral preparation and coated by a complex, so that the palatability of the oral preparation can be significantly improved without influencing the antibacterial effect, and the oral preparation can be developed into a new preparation administrated through the digestive tract to facilitate administration.
Description
Technical field
The invention belongs to livestock and poultry cultivation field, provide especially a kind of treat fowl bacterial intestinal tract disease oral formulations, preparation method and application thereof.
Background technology
Norfloxacin is animal specific quinolone antibiotic kind, has broad-spectrum bactericidal action, all effective to the antibacterial of resting stage and trophophase.Have good antibacterial action to multiple gram negative bacilli and coccus, to the MIC of most sensitive organism bacterial strain all lower than 1 μ g/ml, current norfloxacin is widely used in livestock and poultry cultivation field and is used for the treatment of animal bacteria sexuality dye.
Berberine hydrochloride has another name called berberine, for the alkaloid extracted in the Chinese crude drugs such as Rhizoma Coptidis, Cortex Phellodendri, Radix Berberidis, its has a broad antifungal spectrum, external all have bacteriostasis to multiple Grain-positive and negative bacterium, wherein there is stronger inhibitory action to Hemolytic streptococcus, S. aureus L-forms, vibrio cholera, meningococcus, shigella, Bacillus typhi etc., antibacterial during low concentration, sterilize during high concentration.Infected by influenza, ameba, leptospira, some dermatophytes also have certain inhibitory action.
Current animal bacteria intestinal tract disease is multiple, there will be the drug resistance problems of antibacterial, be used alone a kind of antibacterials and be not enough to effectively treat fowl bacterial intestinal tract disease in the process for the treatment of poultry bacterial infection intestinal tract disease.In addition, in numerous route of administration, oral is that to use the most also be the route of administration of most convenient, but norfloxacin and berberine hydrochloride to eat mouth all very poor, extremely bitter, cannot oral administration or by spice administration, therefore, both are only limitted to injection in the application in livestock and poultry cultivation field for a long time.
Summary of the invention
The object of the present invention is to provide a kind of treat fowl bacterial intestinal tract disease oral formulations, preparation method and application thereof, this oral formulations adopts norfloxacin and berberine hydrochloride drug combination, parcel through coordination compound can significantly improve its palatability when not affecting fungistatic effect, the novel formulation through digestive tract administration can be developed to, facilitate administration.
The present invention specifically provides a kind of oral formulations for the treatment of fowl bacterial intestinal tract disease, it is characterized in that: it is made up of pharmaceutical composition, coating material and pharmaceutic adjuvant, described pharmaceutical composition is made up of norfloxacin and berberine hydrochloride, and described coating material is beta cyclodextrin; The mass ratio of pharmaceutical composition and coating material is 5-2:1.
The oral formulations for the treatment of fowl bacterial intestinal tract disease of the present invention, is characterized in that: the mass ratio of norfloxacin and berberine hydrochloride is 9:2.
The oral formulations for the treatment of fowl bacterial intestinal tract disease of the present invention, is characterized in that: in described oral formulations also have pharmaceutic adjuvant, this pharmaceutic adjuvant be filler, disintegrating agent, wetting agent, plasticizer one or more.One or more of prioritizing selection starch, sucrose, lactose, mannitol, sorbitol, polyvinylpolypyrrolidone, ethanol, methylcellulose, PEG6000.The mass ratio of pharmaceutic adjuvant and pharmaceutical composition is 1:2 ~ 10
Oral formulations of the present invention can administered by oral gavage, through feedstuff or drinking water administration, be specially pulvis, granule, suspensoid, Emulsion, tablet or pill.
Present invention also offers the preparation method of described treatment fowl bacterial intestinal tract disease oral formulations, it is characterized in that, concrete steps are as follows:
1. load in granulator after norfloxacin, berberine hydrochloride being pulverized, adjustment inlet temperature 75 ~ 89 DEG C, leaving air temp 53 ~ 67 DEG C, control blower fan frequency at 40 ~ 50Hz, material is made to mix up and down in granulator and heat, spray into amidin, adjustment atomizing pressure, to 0.2Mpa-0.4Mpa, continues heating and the moisture content in material is volatilized;
2. by step 1. in material continue heating, make it keep the state of fluctuating, beta cyclodextrin aqueous solution sprayed in granulator, make beta cyclodextrin evenly be wrapped in material surface, after drying, cross No. 4, standard sieve;
3. by step 2. in material mix with pharmaceutic adjuvant, sieve after pack and get final product.
Wherein step 1. in inlet temperature be preferably 82 ± 2 DEG C, leaving air temp is preferably 60 ± 2 DEG C, controls blower fan frequency and is preferably 45Hz.
Oral formulations of the present invention can be applied in treatment fowl bacterial intestinal tract disease, and its consumption is add 9g norfloxacin and 2g berberine hydrochloride in every 100kg-200kg feedstuff.
Conbined usage norfloxacin of the present invention and berberine hydrochloride, make it have effect that is collaborative, potentiation, and by adjusting dosage form thus change administering mode, through pharmacokinetics and artificial onset's Experiment on therapy, prove that coating material of the present invention does not affect the bioavailability of medicine, and this oral formulations preparation method is simple, is applicable to producing in enormous quantities, the novel formulation through digestive tract route of administration can be developed to.
Detailed description of the invention
Embodiment 1
Treat an oral formulations for fowl bacterial intestinal tract disease, its preparation process is as follows:
1. after norfloxacin, berberine hydrochloride being pulverized, in loading granulator, (mass ratio of norfloxacin and berberine hydrochloride is 9:2, adjustment inlet temperature is 82 DEG C, leaving air temp 60 DEG C, control blower fan frequency at 45Hz, material is made to mix up and down in granulator and heat, spray into amidin, adjustment atomizing pressure, to 0.2Mpa-0.4Mpa, continues heating and the moisture content in material is volatilized;
2. by step 1. gained material continuation heating, it is made to keep the state of fluctuating, beta cyclodextrin aqueous solution is sprayed into (mass ratio of beta cyclodextrin and drug regimen is 1:2) in granulator, make beta cyclodextrin evenly be wrapped in material surface, after drying, cross No. 4, standard sieve;
3. by step 2. in material mix with sucrose, sieve after packaging.
Gained tablet significantly improves palatability after the parcel of coordination compound, and does not affect fungistatic effect, and pharmacokinetics and artificial onset's therapeutic test all prove that norfloxacin and berberine hydrochloride do not affect its bioavailability after coordination compound wraps up.
Embodiment 2
Be to adjust inlet temperature 76 DEG C with the difference of embodiment 1, leaving air temp 54 DEG C, control blower fan frequency at 41Hz, make pulvis.
Embodiment 3
Be to adjust inlet temperature 88 DEG C with the difference of embodiment 1, leaving air temp 66 DEG C, control blower fan frequency at 49Hz, make Emulsion.
Embodiment 4
Be to adjust inlet temperature 84 DEG C with the difference of embodiment 1, leaving air temp 62 DEG C, control blower fan frequency at 43Hz, make granule.
Embodiment 5
Be to adjust inlet temperature 86 DEG C with the difference of embodiment 1, leaving air temp 64 DEG C, control blower fan frequency at 42Hz, make suspensoid.
Embodiment 6
Be to adjust inlet temperature 87 DEG C with the difference of embodiment 1, leaving air temp 65 DEG C, control blower fan frequency at 48Hz, make pill.
Embodiment 7
Be to adjust inlet temperature 80 DEG C with the difference of embodiment 1, leaving air temp 59 DEG C, control blower fan frequency at 46Hz.
Embodiment 8
Be to adjust inlet temperature 79 DEG C with the difference of embodiment 1, leaving air temp 63 DEG C, control blower fan frequency at 47Hz.
Embodiment 9
Laboratory animal is 20 age in days chickens, and chicken group has symptom of diarrhea, occurs fragmentary dead, is diagnosed as colibacillosis.Morbidity chicken group is divided into 8 groups at random by body weight, often organize 100, embodiment 1,2 pharmacies and berberine hydrochloride are added respectively in feedstuff, successive administration five days, once a day, dosage and experimental result (blank group is diet, does not add medicine) as shown in table 1.
Therapeutic outcome after table 1 chicken group feeding medicine
Interpretation of result: the cure rate being used alone berberine hydrochloride experimental group is lower, be 78%, all lower than medicine prepared by the embodiment of the present invention 1,2, cure rate of suffering from diarrhoea when medicine addition of the present invention is 1.0g/kg feedstuff is higher, mortality rate is lower, and far below blank group.The oral formulations prepared by the known the present invention of above experimental result effect in quality poultry diarrhoea is better, and its curative effect is better than being used alone berberine hydrochloride.
Embodiment 10
Laboratory animal is 15 age in days meat-type duck, and duck group draws watery stools symptom, and has obvious indigested feedstuff in feces, is diagnosed as colibacillosis or infectious serositis in duck.Morbidity duck group is divided into 8 groups at random by body weight, often organize 50, embodiment 3,4 pharmacies and norfloxacin powder is added respectively in feedstuff, successive administration five days, once a day, dosage and experimental result (blank group is diet, does not add medicine) as shown in table 2.
Therapeutic outcome after table 2 duck group feeding medicine
Interpretation of result: the cure rate being used alone norfloxacin experimental group is lower is 76%, and all lower than medicine prepared by the embodiment of the present invention 3,4, medicine diarrhoea cure rate of the present invention is higher, and mortality rate is lower, and far below blank group.The oral formulations prepared by the known the present invention of above experimental result effect in quality poultry diarrhoea is better, and its curative effect is better than being used alone norfloxacin.
Above-described embodiment, only for technical conceive of the present invention and feature are described, its object is to person skilled in the art can be understood content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences done according to spirit of the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (9)
1. treat an oral formulations for fowl bacterial intestinal tract disease, it is characterized in that: it is made up of pharmaceutical composition, coating material and pharmaceutic adjuvant, described pharmaceutical composition is made up of norfloxacin and berberine hydrochloride, and described coating material is beta cyclodextrin; The mass ratio of pharmaceutical composition and coating material is 5-2:1.
2. according to the oral formulations for the treatment of fowl bacterial intestinal tract disease described in claim 1, it is characterized in that: the mass ratio of norfloxacin and berberine hydrochloride is 9:2.
3., according to the oral formulations for the treatment of fowl bacterial intestinal tract disease described in claim 1, it is characterized in that: in described oral formulations also have pharmaceutic adjuvant, this pharmaceutic adjuvant be filler, disintegrating agent, wetting agent, plasticizer one or more; The mass ratio of pharmaceutic adjuvant and pharmaceutical composition is 1:2 ~ 10.
4., according to the oral formulations for the treatment of fowl bacterial intestinal tract disease described in claim 3, it is characterized in that: described pharmaceutic adjuvant be starch, sucrose, lactose, mannitol, sorbitol, polyvinylpolypyrrolidone, ethanol, methylcellulose, PEG6000 one or more.
5. according to the oral formulations for the treatment of fowl bacterial intestinal tract disease described in claim 1, it is characterized in that: described oral formulations is pulvis, granule, suspensoid, Emulsion, tablet or pill.
6. treat a preparation method for fowl bacterial intestinal tract disease oral formulations described in claim 1, it is characterized in that, concrete steps are as follows:
1. load in granulator after norfloxacin, berberine hydrochloride being pulverized, adjustment inlet temperature 75 ~ 89 DEG C, leaving air temp 53 ~ 67 DEG C, control blower fan frequency at 40 ~ 50Hz, material is made to mix up and down in granulator and heat, spray into amidin, adjustment atomizing pressure, to 0.2Mpa-0.4Mpa, continues heating and the moisture content in material is volatilized;
2. by step 1. in material continue heating, make it keep the state of fluctuating, beta cyclodextrin aqueous solution sprayed in granulator, make beta cyclodextrin evenly be wrapped in material surface, after drying, cross No. 4, standard sieve;
3. by step 2. in material mix with pharmaceutic adjuvant, sieve after pack and get final product.
7. according to the preparation method for the treatment of fowl bacterial intestinal tract disease oral formulations described in claim 6, it is characterized in that: step 1. middle inlet temperature is 82 ± 2 DEG C, and leaving air temp is 60 ± 2 DEG C, and controlling blower fan frequency is 45Hz.
8. the application of oral formulations described in claim 1 in treatment fowl bacterial intestinal tract disease.
9., according to the application of oral formulations described in claim 8 in treatment fowl bacterial intestinal tract disease, it is characterized in that: every 9g norfloxacin and 2g berberine hydrochloride are used in 100kg-200kg feedstuff.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410617528.3A CN104434921A (en) | 2014-11-05 | 2014-11-05 | Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410617528.3A CN104434921A (en) | 2014-11-05 | 2014-11-05 | Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104434921A true CN104434921A (en) | 2015-03-25 |
Family
ID=52882186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410617528.3A Pending CN104434921A (en) | 2014-11-05 | 2014-11-05 | Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104434921A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929328A (en) * | 2016-10-13 | 2018-04-20 | 广西普大动物保健品有限公司 | A kind of good ox toad particle manufacture craft of palatability |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433762A (en) * | 2002-01-23 | 2003-08-06 | 李向荣 | New use of fluoroquinolone group medicine and berberine |
| CN101690717A (en) * | 2009-09-30 | 2010-04-07 | 北京大北农动物保健科技有限责任公司 | Valnemulin for livestock and saline premix and preparation method thereof |
| CN101954089A (en) * | 2010-09-08 | 2011-01-26 | 洛阳惠中兽药有限公司 | Animal medicine inclusion compound, preparation method and application thereof |
-
2014
- 2014-11-05 CN CN201410617528.3A patent/CN104434921A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1433762A (en) * | 2002-01-23 | 2003-08-06 | 李向荣 | New use of fluoroquinolone group medicine and berberine |
| CN101690717A (en) * | 2009-09-30 | 2010-04-07 | 北京大北农动物保健科技有限责任公司 | Valnemulin for livestock and saline premix and preparation method thereof |
| CN101954089A (en) * | 2010-09-08 | 2011-01-26 | 洛阳惠中兽药有限公司 | Animal medicine inclusion compound, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 贺月林: "复方诺氟沙星注射液的体外抑菌试验", 《湖南畜牧兽医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929328A (en) * | 2016-10-13 | 2018-04-20 | 广西普大动物保健品有限公司 | A kind of good ox toad particle manufacture craft of palatability |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101428057A (en) | Antimicrobial powder for reinforcing immune, strengthening the body resistance and removing toxicity for livestock and poultry | |
| CN107737106A (en) | Safe ten thousand rhzomorph sol particles of a kind of tartaric acid and preparation method thereof | |
| CN103285374B (en) | A kind of Amoxicillin colistin sulphate granule and preparation method thereof | |
| CN103768026B (en) | Water-soluble micro-powder containing amoxicillin and preparation method thereof | |
| CN104522316A (en) | Composition for preventing and treating chicken enteritis | |
| CN105943629B (en) | Traditional Chinese medicine compound preparation for treating piglet diarrhea and production method thereof | |
| CN105497878A (en) | Compound preparation for treating animal diarrhea and preparation method of compound preparation | |
| CN102526054A (en) | Compound enrofloxacin pellets and preparation method thereof | |
| CN102973690A (en) | Chinese herbal medicine preparation for treating pig gastroenteritis | |
| CN102258635A (en) | Antibacterial Chinese medicine for veterinary use | |
| CN104434921A (en) | Oral preparation for treating bacterial intestinal diseases of livestock and preparation method thereof | |
| CN104490788A (en) | Tiamulin fumarate particles and preparation method thereof | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN102793713A (en) | Lincomycin hydrochloride-spectinomycin sulfate injection and preparation method thereof | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN104784299B (en) | A kind of fermented tcm composition of kuh-seng containing wolf's milk and radix scutellariae and preparation method thereof | |
| JP4809225B2 (en) | Compositions for veterinary and medical applications | |
| CN104688883B (en) | A kind of Chinese medicine composition of kuh-seng containing wolf's milk and radix scutellariae and preparation method thereof | |
| CN106924198A (en) | Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof | |
| CN104188919B (en) | A kind of livestock and poultry Thiamphenicol dried bean noodles supensoid agent and preparation method thereof | |
| KR20200144568A (en) | Drugs, combination products, and applications for preventing and/or treating pain and/or fever | |
| ES2369138T3 (en) | COMPOSITIONS FOR VETERINARY AND MEDICAL APPLICATIONS. | |
| CN105106935A (en) | Compound Flunixin meglumine injection and preparation method thereof | |
| CN108992625A (en) | A kind of drug and preparation method thereof for preventing and treating infectious coryza of chicken | |
| CN107551069A (en) | One kind is used to treat cholera fowl feed addictive and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |